NCT05317741已完成1 期
A Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect, and Pharmacodynamics Following a Single Oral Dose of IA-14069 in Healthy Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Change from baseline in vital signs: Blood pressure (Systolic/Diastolic)
研究概览
简要总结
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, food effect, and pharmacodynamics following a single oral dose of IA-14069 in healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signed the ICF.
- •Male subjects, ≥ 18 to ≤ 55 years of age at the time of signing the ICF.
- •Overtly healthy as determined by medical evaluation including medical history, physical examination and clinical laboratory tests.
- •Body mass index (BMI) within ≥ 18.0 to ≤ 32.0 kg/m2 and body weight not less than 50 kg.
- •Pulse rate between 40 and 100 beats per minutes (bpm)
- •A 12-lead ECG consistent with normal cardiac conduction and function, including:
- •Sinus rhythm
- •QTc interval of ≤ 450 milliseconds (QT interval corrected using Fridericia correction method [QTcF])
- •QRS interval of ≤ 120 milliseconds
- •PR interval ≤ 220 milliseconds
- •Morphology consistent with healthy cardiac conduction and function
- •Non-smoker or ex-smoker for > 6 months.
- •Agree to use contraception (Appendix 1) during the treatment period and for at least 90 days after the last dose of study treatment and refrain from donating sperm during this period.
排除标准
- •Resting BP systolic or diastolic > 140/90 mmHg or < 90/45 mmHg. Subjects BP may be re-checked per site SOPs.
- •Received any investigational drug or used any investigational device within 30 days or 5 half-lives whichever is longer prior to the first dosing of study drug.
- •Clinically significant history of any serious drug sensitivity or allergy, or food allergy as determined by the Investigator (i.e., requiring epinephrine or steroids to treat).
- •Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders or abnormalities, or other major systemic disease that, according to the Investigator, would unduly risk the subject's safety or may impact the conduct of the study.
- •Presence of any disorder that would interfere with the swallowing, absorption, distribution, metabolism and excretion of the investigational product as judged by the Investigator. Surgery for appendicitis is acceptable.
- •Show evidence of significant active neuropsychiatric disease, including taking prescription medication for such diseases (including anti-depressant /anti-anxiety medication).
- •Presence of clinically significant physical, laboratory, or ECG findings at Screening that, in the opinion of the Investigator, may interfere with any aspect of study conduct or interpretation of results, or may present a safety issue to that particular subject. Laboratory results may be re-checked once per Investigator's discretion.
- •Liver function test results of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥ 1.25 upper limit of normal (ULN); with an exception of subjects considered eligible to participate in the study per Investigator's discretion.
- •History of vaso-vagal syncope within 5 years.
- •History of any major surgery within 6 months.
- •History of any active infection within 30 days prior to the first dosing.
- •Known history or positive test of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody (Ab), or human immunodeficiency virus type 1 (HIV-1) or 2 (HIV-2) Ab.
- •Subjects with a positive urine nicotine/cotinine test.
- •History of alcohol abuse as judged by the Investigator within approximately 1 year prior to admission. Average weekly alcohol intake > 14 units/week or are unwilling to stop alcohol consumption from 72 hr prior to dosing and outpatient visits and throughout the in-house periods until discharged from the clinical research unit and are unwilling to limit alcohol consumption during outpatient periods. Positive alcohol test at Screening or admission (One unit of alcohol equals about 12 ounces of beer, 5 ounces of wine or 1.5 ounces of spirits).
- •History of illicit drug abuse, within approximately 1 year prior to admission or evidence of current use as judged by the Investigator. Positive drug test, including marijuana, at Screening or admission.
- •Donation or loss of > 500 mL of blood within 56 days prior to admission.
- •Chronic use of prescription or non-prescription drugs (including vitamins and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme inducer) prior to the first dosing per Investigator's discretion.
- •Unable to comply with the safety monitoring requirements of this clinical study or is considered by the Investigator to be an unsuitable candidate for the study.
研究组 & 干预措施
A mg IA-14069 or Placebo
Experimental
干预措施: IA-14069 (Drug)
A mg IA-14069 or Placebo
Experimental
干预措施: Placebo (Drug)
B mg IA-14069 or Placebo
Experimental
干预措施: IA-14069 (Drug)
B mg IA-14069 or Placebo
Experimental
干预措施: Placebo (Drug)
C mg IA-14069 or Placebo
Experimental
Period 1: Fasted condition → Period 2: Fed condition
干预措施: IA-14069 (Drug)
C mg IA-14069 or Placebo
Experimental
Period 1: Fasted condition → Period 2: Fed condition
干预措施: Placebo (Drug)
D mg IA-14069 or Placebo
Experimental
干预措施: IA-14069 (Drug)
D mg IA-14069 or Placebo
Experimental
干预措施: Placebo (Drug)
E mg IA-14069 or Placebo
Experimental
干预措施: IA-14069 (Drug)
E mg IA-14069 or Placebo
Experimental
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in vital signs: Blood pressure (Systolic/Diastolic)
时间窗: Up to Day 8
Incidence and severity of adverse events
时间窗: Up to Day 14
Change from baseline in vital signs: Heart rate
时间窗: Up to Day 8
Change from baseline in vital signs: Body temperature
时间窗: Up to Day 8
Incidence and severity of clinical laboratory abnormalities
时间窗: Up to Day 8
Hematology, serum chemistry and urinalysis
Incidence and severity of clinical findings on physical examination
时间窗: Up to Day 8
Change from baseline in vital signs: Respiratory rate
时间窗: Up to Day 8
Change from baseline in 12-lead ECG parameters
时间窗: Up to Day 8
PR, QRS, QT and QTc intervals
次要结局
- Time to maximum concentration (Tmax) for IA-14069(Up to Day 8)
- Maximum observed concentration (Cmax) for IA-14069(Up to Day 8)
- PK in Food effect measured by AUC for IA-14069(Up to Day 8)
- Apparent volume of distribution (Vd/F) for IA-14069(Up to Day 8)
- Apparent clearance (CL/F) for IA-14069(Up to Day 8)
- Pharmacokinetic (PK) in Food effect measured by Cmax for IA-14069(Up to Day 8)
- PK in Food effect measured by Tmax for IA-14069(Up to Day 8)
- PK in Food effect measured by t1/2 for IA-14069(Up to Day 8)
- Area under the concentration-time curve (AUC) for IA-14069(Up to Day 8)
- Terminal elimination half-life (t1/2) for IA-14069(Up to Day 8)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Single Dose Study of SHR4640 in Healthy SubjectsHyperuricemia GoutNCT02815839Jiangsu HengRui Medicine Co., Ltd.50
Unknown
1 期
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187OverweightDiabetes Mellitus Type 2 in ObeseNCT01874366Piramal Enterprises Limited96
终止
1 期
Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese SubjectsHealthy, Overweight and/or Obese SubjectsNCT01764425Piramal Enterprises Limited32
已完成
1 期
Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy VolunteersPharmacokineticsSafetyTolerabilityNCT05698095Usona Institute54
撤回
1 期
A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy SubjectsAlopecia AreataNCT06045624Ornovi, Inc.